Why Seres Therapeutics Inc. Stock Is Tanking Today

Shares of Seres Therapeutics (NASDAQ: MCRB), a clinical-stage biotech focused on microbiome therapeutics, were down 19% as of 11:25 a.m. EDT on Monday. The decline can be traced to the release of less-than-stellar news from a phase 1 clinical trial.

Seres reported top-line results from a phase 1b study today. This study was evaluating its compound SER-287 as a hopeful treatment for ulcerative colitis.

Here are the key headlines from the study that management is trying to get investors to focus on:

Source: Fool.com